Background: The efficacy and safety of tolvaptan (TLV) in patients with chronic heart failure (CHF) are unclear. Aim: The aim of this study was to evaluate the efficacy and safety of tolvaptan (TLV) versus conventional therapy, primarily furosemide (FRM). In addition, the effect of the nutritional status on the efficacy of TLV was evaluated. Method: This retrospective study included patients with CHF who were hospitalised and treated between March 2015 and February 2019, including 51 patients in the FRM group and 63 patients in the TLV group. Result: Weight loss did not differ between the FRM and TLV groups (−2.1 AE 2.1 kg vs −1.5 AE 3.5 kg, p = 0.250). After 7 days, the change in the estimated glomerular filtration rate was significantly smaller in the FRM group (56.5 AE 22.2 vs 51.9 AE 20.0 mL/min/ 1.73 m 2 , p = 0.002). There was no significant difference in serum sodium (Na) levels between days 0 and 7 in the FRM group (138.8 AE 5.2 vs 139.2 AE 3.9 mEq/L, p = 0.487). However, the serum Na level was significantly increased in the TLV group (138.4 AE 5.0 mEq/L vs 139.4 AE 4.0 mEq/L, p = 0.047). There was no significant correlation between weight loss due to diuresis and the objective prognostic nutritional index in either group. Conclusion:In hyponatremic patients with CHF, TLV may be more effective than FRM in slowing the course of renal damage and elevating serum Na levels; however, nutritional indices may not be necessary to consider while administering TLV.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.